[HTML][HTML] The skin prick test–European standards

L Heinzerling, A Mari, KC Bergmann… - Clinical and translational …, 2013 - Springer
Skin prick testing is an essential test procedure to confirm sensitization in IgE-mediated
allergic disease in subjects with rhinoconjunctivitis, asthma, urticaria, anapylaxis, atopic …

[HTML][HTML] Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts

S Haggenmüller, RC Maron, A Hekler, JS Utikal… - European Journal of …, 2021 - Elsevier
Background Multiple studies have compared the performance of artificial intelligence (AI)–
based models for automated skin cancer classification to human experts, thus setting the …

Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology

MP Bonaca, BA Olenchock, JE Salem, SD Wiviott… - Circulation, 2019 - Am Heart Assoc
Recent developments in cancer therapeutics have improved outcomes but have also been
associated with cardiovascular complications. Therapies harnessing the immune system …

Myocarditis in patients treated with immune checkpoint inhibitors

SS Mahmood, MG Fradley, JV Cohen, A Nohria… - Journal of the American …, 2018 - jacc.org
Background: Myocarditis is an uncommon, but potentially fatal, toxicity of immune checkpoint
inhibitors (ICI). Myocarditis after ICI has not been well characterized. Objectives: The authors …

[HTML][HTML] Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

L Hofmann, A Forschner, C Loquai… - European journal of …, 2016 - Elsevier
Background Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective
treatment option for metastatic melanoma as well as for other cancer entities. They act via …

[HTML][HTML] Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

L Zimmer, SM Goldinger, L Hofmann, C Loquai… - European journal of …, 2016 - Elsevier
Background Anti-programmed cell death 1 (PD-1) antibodies represent an effective
treatment option for metastatic melanoma and other cancer entities. They act via blockade of …

Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab

B Weide, A Martens, JC Hassel, C Berking… - Clinical Cancer …, 2016 - AACR
Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as
these may influence individual treatment selection or sequence. We aimed to identify …

[HTML][HTML] The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

CJ Voskens, SM Goldinger, C Loquai, C Robert… - PloS one, 2013 - journals.plos.org
Background Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody,
has been approved for the treatment of metastatic melanoma and induces adverse events …

[HTML][HTML] Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

L Heinzerling, PA Ott, FS Hodi, AN Husain… - … for immunotherapy of …, 2016 - Springer
Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses
in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal …

[HTML][HTML] Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task

TJ Brinker, A Hekler, AH Enk, J Klode… - European Journal of …, 2019 - Elsevier
Background Recent studies have successfully demonstrated the use of deep-learning
algorithms for dermatologist-level classification of suspicious lesions by the use of excessive …